Global Pulmonary Embolism Market

Global Pulmonary Embolism Market Insights Forecasts to 2035

• The Global Pulmonary Embolism Market Size Was valued at USD 1.94 Billion in 2024
• The Global Pulmonary Embolism Market Size is Expected to Grow at a CAGR of around 8.36% from 2025 to 2035
• The Worldwide Pulmonary Embolism Market Size is Expected to Reach USD 4.69 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

 

 

According to a research report published by Decisions Advisors and Consulting, the global pulmonary embolism market size was worth around USD 1.94 Billion in 2024 and is predicted to grow to around USD 4.69 Billion by 2035 with a compound annual growth rate (CAGR) of 8.36% from 2025 to 2035. Future opportunities in the global pulmonary embolism market include advanced diagnostic imaging adoption, development of novel anticoagulants, minimally invasive catheter-based therapies, AI-enabled risk prediction, expanding telemedicine services, and improving emergency care infrastructure.

 

Market Overview

The global pulmonary embolism market refers to the worldwide industry which specializes in diagnosing and treating and managing pulmonary embolism, which is a dangerous medical condition that occurs when blood clots obstruct lung arteries and prevent normal breathing while creating severe health risks. The market includes anticoagulant drugs and thrombolytic therapy and surgical and catheter-based interventions and advanced diagnostic imaging technologies. The rising prevalence of cardiovascular diseases together with an aging population and increasing numbers of people who lead inactive lifestyles and the development of better emergency medical services create growth drivers for the industry. The rising public awareness together with early detection initiatives creates a greater need for prompt treatment. The development of new oral anticoagulants and less invasive catheter-based therapies and artificial intelligence diagnostic systems and telemedicine systems for instant medical consultation and healthcare infrastructure expansion in developing nations bring new business opportunities which will lead to improved patient outcomes and wider access to medical services and faster diagnostic processes.

 

Report Coverage

This research report categorizes the pulmonary embolism market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the pulmonary embolism market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the pulmonary embolism market. 

 

Driving Factors

The global pulmonary embolism market expansion results from multiple factors which include increasing cardiovascular disease rates and the growing number of elderly people together with the rise of inactive lifestyles and the increased public knowledge about early disease detection methods. The system allows quick medical treatment through its combination of improved medical imaging techniques and efficient emergency response capabilities. The market expansion is driven by new medical technologies which include catheter-directed thrombolysis and novel oral anticoagulants and AI-based diagnostic tools and minimally invasive procedures.

 

Restraining Factors

The market growth faces obstacles from high treatment costs, delayed diagnosis, limited public knowledge, bleeding complications risks associated with anticoagulants, strict requirements for regulatory approvals, developing regions' insufficient healthcare facilities, and their restricted availability of advanced diagnostic equipment.

 

Market Segmentation

The pulmonary embolism market share is classified into symptoms and diagnosis.

• The shortness of breath segment dominated the market in 2024, approximately 42% and is projected to grow at a substantial CAGR during the forecast period.

Based on the symptoms, the pulmonary embolism market is divided into shortness of breath, chest pain, cough, irregular heartbeat, dizziness, fever, cyanosis, and others. Among these, the shortness of breath segment dominated the market in 2024, approximately 42% and is projected to grow at a substantial CAGR during the forecast period. The main symptoms of pulmonary embolism which require urgent medical care. The system identifies early symptoms which lead to increased diagnosis rates and treatment requests. The market segment sustains its dominance because the condition affects all age groups and severity levels while public awareness campaigns and modern diagnostic methods continue to spread.

 

 

• The CT scan segment accounted for the largest share in 2024, approximately 48% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the diagnosis, the pulmonary embolism market is divided into chest X-Ray, ECG, MRI, CT scan, pulmonary angiography, venography, venous ultrasound, D-dimer test, and others. Among these, the CT scan segment accounted for the largest share in 2024, approximately 48% and is anticipated to grow at a significant CAGR during the forecast period. The system detects pulmonary embolism through rapid and precise non-invasive methods which enable doctors to detect the condition at an early stage and start treatment without delay. The diagnostic tool achieves high market share because hospitals widely use it to detect clots with high accuracy and it helps doctors make treatment choices.

 

Regional Segment Analysis of the Pulmonary Embolism Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the pulmonary embolism market over the predicted timeframe.

North America is anticipated to hold the largest share of the pulmonary embolism market over the predicted timeframe. The combination of advanced healthcare infrastructure and high per capita healthcare spending and widespread access to diagnostic tools such as CT scans and early adoption of new anticoagulant drugs and the strong presence of major pharmaceutical companies and favorable insurance and reimbursement systems. The market leads through awareness campaigns and dedicated treatment facilities which provide instant diagnosis and comprehensive patient care.

 

Asia-Pacific is expected to grow at a rapid CAGR in the pulmonary embolism market during the forecast period. The region experiences market growth through four factors which include government healthcare initiatives and improved insurance coverage and expanding hospital infrastructure and the usage of new anticoagulant drugs together with minimally invasive treatment methods. First two factors create market growth through government healthcare initiatives and better insurance coverage while hospital infrastructure development and new treatment methods drive market expansion.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the pulmonary embolism market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Abbott
• F. Hoffmann-La Roche Ltd.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GSK plc
• Bristol-Myers Squibb Company
• Hikma Pharmaceuticals PLC
• Johnson & Johnson and its affiliates
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In July 2024, Aventus Medical announced that its Aventus Thrombectomy System had received U.S. FDA clearance for the treatment of pulmonary embolism (PE). The device was designed to remove thrombus efficiently while minimizing blood loss, offering an advanced option for interventional treatment of PE patients. This clearance marked a significant milestone in expanding minimally invasive options for PE management and underscored Aventus Medical’s commitment to advancing vascular intervention technologies.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the pulmonary embolism market based on the below-mentioned segments: 

 

Global Pulmonary Embolism Market, By Symptoms

• Shortness of Breath
• Chest Pain
• Cough
• Irregular Heartbeat
• Dizziness
• Fever
• Cyanosis
• Others

 

Global Pulmonary Embolism Market, By Diagnosis 

• Chest X-Ray
• ECG
• MRI
• CT Scan
• Pulmonary Angiography
• Venography
• Venous Ultrasound
• D-Dimer Test
• Others

 

Global Pulmonary Embolism Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is the projected growth of the global pulmonary embolism market?

A: The market is expected to grow from USD 1.94 billion in 2024 to USD 4.69 billion by 2035, at a CAGR of 8.36%, driven by rising cardiovascular disease prevalence and improved diagnostics.

 

2. Which symptom segment dominates the pulmonary embolism market?

A: The shortness of breath segment dominated with approximately 42% share in 2024, due to its prevalence as a critical, early symptom prompting urgent diagnosis and treatment.

 

3. Which diagnostic method holds the largest market share?

A: CT scans accounted for about 48% of the market in 2024, favored for rapid, accurate, and non-invasive detection, widely used in hospitals for early pulmonary embolism diagnosis.

 

4. Why does North America hold the largest market share?

A: North America leads due to advanced healthcare infrastructure, high per capita spending, early adoption of novel anticoagulants, widespread diagnostic tools, pharmaceutical presence, reimbursement policies, and specialized treatment facilities.

 

5. Why is Asia-Pacific the fastest-growing region?

A: Asia-Pacific grows rapidly from government healthcare initiatives, expanding insurance coverage, hospital infrastructure development, and adoption of minimally invasive treatments and novel anticoagulant drugs for pulmonary embolism management.